The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01B | Antimetabolites | |
4
|
L01BC | Pyrimidine analogues | |
5
|
L01BC58 |
| Active Ingredient |
|---|
|
Decitabine is a nucleoside metabolic inhibitor that is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation and/or apoptosis. Cedazuridine inhibits cytidine deaminase (CDA), an enzyme that is responsible for the degradation of cytidine nucleosides, including the cytidine analog decitabine. Oral administration of cedazuridine with decitabine increases the systemic exposure of decitabine via inhibition of first pass metabolism of decitabine in the gut and liver by CDA. |
| Document | Type | Information Source | |
|---|---|---|---|
| INAQOVI Film-coated tablet | MPI, EU: SmPC | European Medicines Agency (EU) | |
| INQOVI Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.